Evaluation of intravenous allopurinol (NSC-1390) in pediatric neoplasia.
D000493:Allopurinol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy; D002648:Child; D004341:Drug Evaluation; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007231:Infant, Newborn; D007275:Injections, Intravenous; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008113:Liver Neoplasms / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D012075:Remission, Spontaneous; D014527:Uric Acid / Q000097:blood
D014527:Uric Acid; D000493:Allopurinol